This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe
by Zacks Equity Research
While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.
Novavax (NVAX) Concentrates on COVID-19 Vaccine Development
by Zacks Equity Research
While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.
Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.
Incyte's (INCY) Going Gets Rough Despite Recent Approvals
by Zacks Equity Research
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill
by Zacks Equity Research
Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.
Pre-Markets Back to Green Ahead of Economic & Earnings Data
by Mark Vickery
After a down day yesterday, we see the Dow +30 points, the S&P 500 +3 points and the Nasdaq +33.
Markets Await Economic and Earnings Data
by Zacks Equity Research
Markets Await Economic and Earnings Data
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $42.06 in the latest trading session, marking a -0.92% move from the prior day.
Pfizer (PFE) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx
Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for USMC
Top Analyst Reports for Pfizer, American Tower & Intuitive Surgical
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), American Tower Corporation (AMT), and Intuitive Surgical, Inc. (ISRG).
Cousins Properties' (CUZ) Heights Union Buyout Fails to Drive Stock
by Zacks Equity Research
The acquisition of Heights Union is in line with Cousins Properties' (CUZ) efforts to enhance its portfolio quality with trophy assets.
Voyager (VYGR) Surges on Gene Therapy Deal With Pfizer
by Zacks Equity Research
Voyager (VYGR) signs agreement with Pfizer granting the latter with rights to develop novel capsids using Voyager's proprietary technology for Pfizer's gene therapies and options for exclusive license to the capsids.
Down 9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Top Ranked Income Stocks to Buy for October 7th
by Zacks Equity Research
OXLC, ING, PFE, and BRT made it to the Zacks Rank #1 (Strong Buy) income stocks list on October 7, 2021
Vaxart (VXRT) Starts Recruitment in Oral COVID-19 Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) commences recruiting subjects in its mid-stage study for its oral vaccine tablet for COVID-19. It will begin dosing in the United States later this month.
Moderna (MRNA) Gets EMA Authorization for SpikeVax Third Dose
by Zacks Equity Research
Moderna (MRNA) gets authorization for the third dose of its COVID-19 vaccine, Spikevax, for use in immunocompromised individuals in Europe.
J&J (JNJ) Seeks FDA Authorization for COVID-19 Booster Jab
by Zacks Equity Research
J&J (JNJ) submits data to the FDA to support an authorization for the booster dose of its single-shot COVID-19 vaccine.
Biotech Stock Roundup: MRNA's Vaccine Update, GILD's CAR T Therapy Label Expansion
by Ekta Bagri
Regulatory and pipeline updates from bigwigs like Moderna (MRNA) and Gilead (GILD) have been the biotech sector's few key highlights during the past week.
Should You Invest in Travel & Tourism ETFs Now?
by Neena Mishra
Travel stocks could benefit from pent-up demand as we return to normal
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates when Tilray (TLRY) reports first-quarter fiscal 2022 results.
RedHill (RDHL) COVID Pneumonia Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Redhill's (RDHL) opaganib achieves a significant reduction in mortality in hospitalized patients with severe COVID-19 pneumonia based on new data from the phase II/III study.